MedPath

Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis

Not Applicable
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Other: patientMpower platform
Other: usual care
Registration Number
NCT03104322
Lead Sponsor
patientMpower Ltd.
Brief Summary

Pilot-scale, open-label, fixed-order, two-period crossover study in idiopathic pulmonary fibrosis (IPF) over 16 weeks. Patients will use an electronic health journal (patientMpower platform) to record treatment compliance, forced vital capacity (FVC; daily), impact of IPF on daily life (weekly) and other symptoms. Objectives are to characterise acceptability of patientMpower platform from patient \& healthcare professional perspective, impact of active engagement and self-monitoring using patientMpower platform on Patient Reported Outcome Measures (PROMs) in IPF, impact of patientMpower platform on medication compliance and correlation between patient-reported PROMs \& FVC and clinical outcomes.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
7
Inclusion Criteria
  • confirmed diagnosis of idiopathic pulmonary fibrosis (IPF).
  • daily unrestricted access to smartphone or tablet device at home.
  • demonstrated understanding of protocol and correct use of Spirobank Smart spirometer and patientMpower platform.
  • able and willing to perform spirometry every day at home.
  • willing to give written informed consent
Exclusion Criteria
  • significant confusion or any concomitant medical condition which would limit the ability of the patient to record symptoms or use a home spirometer on a regular basis.
  • new prescription of antifibrotic therapy for IPF (e.g. pirfenidone, nintedanib) within 4 weeks before baseline visit.
  • recent exacerbation of IPF or other clinically significant change in the patient's medical condition in 4 weeks before baseline visit

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Observation sequencepatientMpower platformPeriod 1: patientMpower platform+usual care for 8 weeks; Period 2: usual care alone for 8 weeks
Observation sequenceusual carePeriod 1: patientMpower platform+usual care for 8 weeks; Period 2: usual care alone for 8 weeks
Primary Outcome Measures
NameTimeMethod
Acceptability of patientMpower Platform From Patient & Healthcare Professional Perspectivesingle measurement at 8 weeks

Questionnaire-based assessment of response to questions: \[pMp = patientMpower platform\]

1. instructions for using pMp were clear

2. pMp helped me take the correct dose medicines

3. pMp helped me to take my medicines at the correct time

4. pMp helped me to reach my personal exercise goal

5. pMp helped me to walk further

6. pMp gave me a greater sense of control

7. useful to be able to record the impact of lung fibrosis on QoL

8. pMp encouraged me to look at the informational videos

9. preference for using pMp

10. difficulty in using pMp

11. effect of pMp on impact on daily life

12. tiring/irritating to use pMp

13. want to continue using pMp after study

14. would recommend pMp to others Possible responses Q1-8, Q12: strongly agree/agree/disagree/strongly disagree Q9: yes/no preference/no Q10: very easy/easy/difficult/very difficult Q11: positive/negative/open text Q13,14: yes/no

Secondary Outcome Measures
NameTimeMethod
Patient-reported Forced Vital Capacity (FVC)8 weeks

Forced vital capacity recorded via patientMpower platform daily

Patient-reported Exercise Performance8 weeks

Activity (steps/day) recorded via FitBit or patient's phone and transmitted to patientMpower platform

Medication Compliance (Days Medication Taken/Observation Period Days)8 weeks

Compliance recorded by patient via patientMpower platform daily

Idiopathic Pulmonary Fibrosis Patient Reported Outcome Measure (IPF-PROM)Baseline visit

12-item questionnaire with 4 domains (psychological experience of dyspnoea, physical experience of dyspnoea, emotional well-being, energy levels). 3 questions/domain asking frequency of symptom or its impact in the time interval since last response. Four possible responses to each question: none of the time/some of the time/most of the time/all of the time. Numerical score assigned to each response 1/2/3/4 (respectively). Impact on domain characterised by mean score for each of 3 questions in that domain. One question on overall quality of life with responses: excellent/good/fair/poor/very poor. Numerical score assigned to each response 1/2/3/4/5 respectively. Low score better outcome; high score worse outcome (for all responses).

Trial Locations

Locations (1)

Dept. of Respiratory Medicine

🇮🇪

Galway, Ireland

© Copyright 2025. All Rights Reserved by MedPath